FDA Approves BTG plc's Drug for Cancer Toxicity

U.S. health regulators gave the nod on Tuesday to a drug from British specialty drugmaker BTG Plc that helps cancer patients get rid of toxic levels of a chemotherapy treatment. The drug, called Voraxaze, helps eliminate methotrexate in patients whose kidney function has been compromised by treatment with high doses of the chemotherapy agent. Methotrexate is normally eliminated from the body by the kidneys, but prolonged high doses of the drug used to treat cancer can result in kidney failure. BTG's injectable treatment can quickly break down the chemotherapy medicine and allow the body to expel it.